SCHEMBL9608841

SCHEMBL9608841

Cc1noc(C(=O)N(C)C)n1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.36
DPP8 Q6V1X1 1/20 0.36
HDAC4 P56524 2/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAP4K1 Q92918 1/20 0.33
CXCR1 P25024 1/20 0.32
CXCR2 P25025 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC7 Q8WUI4 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC10 Q969S8 1/20 0.30
HDAC11 Q96DB2 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
HDAC9 Q9UKV0 1/20 0.30
HDAC5 Q9UQL6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12496150 0.86 DPP4 (0.33) DPP4DPP8
SCHEMBL19086975 0.78 HDAC4 (0.33) HDAC4RAB9ASMN1; SMN2
SCHEMBL1326724 0.76
SCHEMBL1829391 0.76
SCHEMBL12410864 0.75 PIK3CG (0.38) HDAC4RAB9ASMN1; SMN2ALDH1A1
SCHEMBL15161301 0.75 LOX (0.33) HDAC4RAB9ASMN1; SMN2
SCHEMBL12500180 0.75 HDAC4 (0.32) HDAC4RAB9ASMN1; SMN2ALDH1A1
SCHEMBL18336585 0.74 HCAR2 (0.38) DPP4DPP8HDAC4ALDH1A1HDAC3
SCHEMBL4832820 0.74
Hydrochloric Acid SCHEMBL8531893 0.73 LOX (0.33) HDAC4RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 EP disclosed
WO-2012069605-A1 NOVEL E,E-DIENE COMPOUNDS AND THEIR USE AS MEDICAMENTS AND COSMETICS DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2012-05-31 WO disclosed
US-20100016383-A1 4-(3,3-DIHALO-ALLYLOXY)PHENOL DERIVATIVES HAVING PESTICIDAL PROPERTIES SYNGENTA CROP PROTECTION, INC. (US) 2010-01-21 US disclosed
US-20100016383-A1 4-(3,3-DIHALO-ALLYLOXY)PHENOL DERIVATIVES HAVING PESTICIDAL PROPERTIES SYNGENTA CROP PROTECTION, INC. (US) 2010-01-21 US disclosed
US-7608631-B2 4-(3,3-dihalo-allyloxy) phenol derivatives having pesticidal properties SYNGENTA CROP PROTECTION, INC. (US) 2009-10-27 US disclosed
US-7608631-B2 4-(3,3-dihalo-allyloxy) phenol derivatives having pesticidal properties SYNGENTA CROP PROTECTION, INC. (US) 2009-10-27 US disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD DPP4 899/4885DPP8 1144/4885HDAC4 909/4885
US-20100016383-A1 4-(3,3-DIHALO-ALLYLOXY)PHENOL DERIVATIVES HAVING PESTICIDAL PROPERTIES DDT, QSOX1, SCO2 DPP4 2982/4885DPP8 3040/4885HDAC4 3096/4885
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 DPP4 1293/4885DPP8 1695/4885HDAC4 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.